Kiniksa Pharmaceuticals International Plc

Explore how Kiniksa Pharmaceuticals’ record‑breaking Q1, driven by ARCALYST and Regeneron partnership, spurs analyst upgrades and positions it as a high‑growth biotech contender.

Kiniksa Pharmaceuticals International Plc has reported a strong start to 2025, with increased revenue guidance and solid Q1 earnings, positioning the company as a key player in the biotechnology sector.